‍Helsinki, Finland, October 27, 2025: Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, announced a partnership with Revio Therapeutics, a specialty pharma company focused on repurposing and optimizing approved medicines, to co-develop and commercialize GLIORA—a nano-formulated combination of olaparib and temozolomide designed as a long-acting, locally delivered thermo-responsive hydrogel for the treatment of high-grade glioma, an aggressive form of brain tumor. The novel GLIORA formulation aims to improve post-surgical tumor control by enabling localized, sustained drug release at the tumor site, thereby enhancing efficacy while minimizing systemic side effects. The collaboration leverages Nanoform’s proprietary CESS® and hydrogel technologies alongside Revio’s clinical development expertise, with clinical entry expected in the second half of 2026.

GLIORA aims to address key challenges associated with the current standard-of-care oral temozolomide (TMZ) by enabling localized, long-acting drug delivery directly to the tumor resection cavity during surgery. The formulation integrates olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor with complementary mechanisms to temozolomide, to potentiate chemo- and radiotherapy-induced DNA damage while inhibiting tumor DNA repair. This localized combination strategy is designed to achieve improved tumor control during the critical post-operative phase, potentially reducing recurrence or resistance while minimizing systemic exposure and side effects.

According to Prof. Edward Hæggström, CEO of Nanoform, achieving such localized, controlled, and sustained delivery within a confined tumor void demands precise control over multiple formulation parameters including particle size, morphology, drug loading, release kinetics, and dose ratio. “This is precisely where Nanoform’s proprietary technologies excel,” he noted. “We’re pleased to collaborate once again with Revio Therapeutics on developing an impactful therapy that could address the significant unmet needs of glioma patients globally.”

Commenting on the collaboration, Sreevatsa Natarajan, CEO of Revio Therapeutics, said, “Partnering with Nanoform on GLIORA represents a major step forward in our efforts to redefine glioma treatment. By combining the synergistic mechanisms of temozolomide and olaparib in a sustained, locally delivered hydrogel, we aim to achieve deeper, longer-lasting tumor control with fewer systemic complications. As one of Revio’s flagship repurposing programs, GLIORA exemplifies our vision of accelerating meaningful innovation through intelligent drug reformulation.”

Although olaparib has not yet been approved for glioblastoma multiforme (GBM), prior clinical evaluations combining it orally with TMZ have demonstrated encouraging results, albeit constrained by systemic toxicity.

Under the partnership terms, Nanoform will employ its proprietary Controlled Expansion of Supercritical Solutions (CESS®) and thermo-responsive hydrogel technologies under GMP conditions at its Helsinki facility to nanoformulate the active ingredients and develop the finished product prototype. Revio Therapeutics will lead the program’s preclinical and clinical development and oversee the eventual manufacturing and supply of the sterile dosage form.

Prototype development and validation are currently in advanced stages, with first-in-human trials anticipated in the second half of 2026. Pending successful clinical outcomes, GLIORA could reach the market between 2029 and 2030. Both companies will share development costs, licensing, and commercialization revenues equally, with Nanoform also eligible to receive €1.5 million in accelerated revenue-share payments.

For more details, you can read Nanoform’s official press release on the collaboration here

‍

About Nanoform

Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se.

For more information, please visit www.nanoform.com.

About Revio Therapeutics

Revio Therapeutics is a privately held, India-HQ, specialty pharmaceutical company that is reimagining proven drugs into faster, lower-risk innovations. Leveraging its proprietary AI platform, rethink Tx™, Revio identifies and develops differentiated therapies using clinically validated molecules, advanced formulations, and capital-efficient 505(b)(2) / EU-Hybrid pathways. Revio’s pipeline spans products that cater to under-served niche or orphan indication spaces. Revio employs a variety of formulation & drug-device combination approaches with the aim of addressing residual unmet needs of patients and accelerating impact while reducing development risk and cost.

For more information, please visit www.reviotx.com.

‍